Developer docs
API playgroundTry for free, no card

Search company profiles

Alkeus Pharmaceuticals

Full company profile

uuid0000ipw

Namestring
Alkeus Pharmaceuticals
Legal namestring
Alkeus Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Alkeus Pharmaceuticals, Inc. is a privately-held, clinical-stage biopharmaceutical company headquartered at 44 Brattle Street, Cambridge, Massachusetts. Founded in 2010 by Dr. Ilyas Washington and Dr. Leonide Saad, the company is developing a single lead investigational therapy, oral gildeuretinol acetate (ALK-001), a new molecular entity designed to reduce the dimerization of vitamin A in the retina without modulating the visual cycle — a mechanism intended to prevent the accumulation of toxic vitamin A dimers that drive progression of Stargardt disease and geographic atrophy secondary to age-related macular degeneration. The company is pre-revenue and has no commercialized products.

The clinical pipeline is structured around three core programs. The pivotal global Phase 3 NORTHSTAR study is enrolling approximately 230 participants aged 8 to 45 with Stargardt disease across 55 sites in more than 11 countries, with primary endpoint of atrophic lesion growth rate. The TEASE program (four studies: TEASE-1 and TEASE-2 completed, TEASE-3 and TEASE-4 ongoing) covers Stargardt patients across advanced, moderate, and early-stage disease plus an open-label extension; TEASE-1 demonstrated a 21.6% reduction in atrophic lesion growth versus placebo (p<0.001). The SAGA study in 198 patients with geographic atrophy showed a 15.3% statistically significant reduction in GA lesion growth from 6 to 24 months (p=0.047) and preservation of 4.4 letters of low luminance visual acuity (p=0.031). Cumulative exposure exceeds 400 patients with a well-tolerated safety profile.

Alkeus's business model is a standard specialty pharmaceutical one-time license / prescription-revenue model contingent on FDA approval, with planned commercialization through traditional pharmaceutical distribution channels targeting retina specialists. The company is backed by institutional investors led by Bain Capital Life Sciences, which led a $150 million Series B financing in June 2023 alongside Sofinnova Investments, TCG Crossover, and Wellington Management. Gildeuretinol has received Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA, plus Orphan Medicinal Product designation from the EMA. Leadership was substantially rebuilt in 2024-2025 with the appointment of Michel Dahan (President and CEO, formerly COO of Akebia Therapeutics), David Arkowitz (CFO), Tamara Dillon (CHRO), Eric Trachtenberg (CLO), Srinivas Duggirala (SVP, Technical Operations), and Carlos Quezada-Ruiz (CMO, formerly SVP/Ophthalmology Therapeutic Area Head at 4D Molecular Therapeutics and senior leader at Genentech/Roche ophthalmology).

Short descriptiontext

Alkeus Pharmaceuticals is a private, clinical-stage biopharmaceutical company developing oral gildeuretinol acetate (ALK-001), an investigational therapy that reduces toxic vitamin A dimerization for Stargardt disease and geographic atrophy secondary to AMD. The Cambridge, Massachusetts company is conducting a pivotal global Phase 3 program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, retinal disease therapeutics, Stargardt disease treatment, geographic atrophy therapy, investigational drug development
Industry3 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Ophthalmic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing gildeuretinol (ALK-001) for Stargardt disease and geographic atrophy. The company plans to commercialize the therapy upon FDA approval.

alkeuspharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company developing gildeuretinol acetate (ALK-001), an oral investigational therapy designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. The product is being advanced in clinical trials for Stargardt disease (TEASE program and pivotal Phase 3 NORTHSTAR study) and geographic atrophy secondary to age-related macular degeneration (SAGA study). The company is pre-revenue and intends to commercialize the therapy upon FDA approval, distributing it through traditional pharmaceutical channels prescribed by retina specialists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 21.6% reduction in atrophic retinal lesion growth vs placebo (p<0.001) in TEASE-1 study
+3 more records
Product overview1 text field

Alkeus Pharmaceuticals is a biopharmaceutical company developing a single lead candidate, gildeuretinol acetate (ALK-001), an oral new molecular entity designed to reduce toxic vitamin A dimerization without modulating the visual cycle. The product is being advanced through multiple clinical trial programs: the pivotal Phase 3 NORTHSTAR Study for Stargardt disease, the TEASE program (four studies spanning advanced, moderate, early-stage, and extension phases) for Stargardt disease, and the SAGA study for geographic atrophy secondary to AMD. The company has no commercialized products and all offerings are investigational therapies in clinical development.

Product and service4 records
1Gildeuretinol Acetate (ALK-001)
CategoryInvestigational ophthalmic drug product
Description

Oral investigational new molecular entity (capsule, once daily) designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. It is Alkeus's lead clinical candidate, in development for Stargardt disease and geographic atrophy secondary to age-related macular degeneration.

2NORTHSTAR Phase 3 Study (Gildeuretinol)
CategoryClinical trial program
Description

Pivotal clinical trial program evaluating oral gildeuretinol acetate in patients with Stargardt disease; designed to support regulatory approval.

3TEASE Program (TEASE-1, TEASE-2, TEASE-3, TEASE-4)
CategoryClinical trial program
Description

Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) program—four studies across advanced, moderate, early-stage, and extension phases evaluating oral gildeuretinol in Stargardt disease.

4SAGA Study (Gildeuretinol in Geographic Atrophy)
CategoryClinical trial program
Description

Clinical study evaluating oral gildeuretinol in 198 patients with geographic atrophy (GA) secondary to age-related macular degeneration, with the primary efficacy endpoint of GA lesion growth rate measured by Fundus Autofluorescence.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeGTM or Marketing Partner
Description

Alkeus serves as Silver Sponsor for Prevent Blindness's third annual Inherited Retinal Disease (IRD) and Genetic Testing Month initiative. The partnership supports education about Stargardt disease and genetic testing for early diagnosis and treatment planning.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage biotech with Syfovre (pegcetacoplan) approved for geographic atrophy secondary to AMD. Directly comparable to Alkeus because both target the same large GA population with a retinal-disease focus, although Apellis uses a complement-inhibitor intravitreal approach versus gildeuretinol's oral vitamin A dimerization mechanism.

TypeDirect peer
Description

Acquired Iveric Bio and now markets Izervay (avacincaptad pegol) for geographic atrophy secondary to AMD. A direct competitor in the GA market and a benchmark for late-stage ophthalmology biotech acquisition by big pharma — a relevant strategic exit template for Alkeus.

TypeDirect peer
Description

Clinical-stage gene therapy company targeting inherited retinal diseases including ABCA4-related conditions. Highly comparable to Alkeus because it operates in the same rare ophthalmology space with a focus on inherited retinal dystrophies, and its former SVP/Ophthalmology TA Head (Carlos Quezada-Ruiz) is now Alkeus's CMO.

TypeDirect peer
Description

Clinical-stage ophthalmology company developing therapeutics for retinal diseases including AMD. Comparable to Alkeus as a retinal-focused biotech pursuing novel mechanisms for high-prevalence retinal indications with a similar pre-commercial, late-stage clinical profile.

TypeDirect peer
Description

Gene therapy company focused on serious ocular diseases, with lead programs in wet AMD and diabetic macular edema. Comparable as a late-stage ophthalmology biotech targeting retinal vascular and degenerative indications with a similar clinical-stage, capital-intensive profile.

TypeDirect peer
Description

Clinical-stage gene therapy company with programs in retinal diseases (wet AMD, diabetic retinopathy) and rare ophthalmology. Comparable to Alkeus as a retinal-disease-focused biotech pursuing novel modality approaches for sight-threatening conditions.

TypeEmerging player
Description

Clinical-stage biotech developing therapies for rare ocular and inflammatory diseases, including retinitis pigmentosa and other retinal conditions. Comparable to Alkeus as a small-cap, late-clinical-stage rare-ophthalmology biotech with similar regulatory pathway dynamics.

TypeEmerging player
Description

Clinical-stage biotech with a lead program (vonaprument) in geographic atrophy secondary to AMD. Comparable to Alkeus as a clinical-stage retina competitor in GA with similar pre-commercial profile and indication overlap.

TypeEmerging player
Description

Clinical-stage biotech with a pipeline including inherited retinal disease programs (e.g., Stargardt and other ABCA4-related dystrophies via OCU410ST). Direct competitor to Alkeus in Stargardt disease, pursuing a gene-therapy modifier approach rather than an oral small molecule.

TypeBroad incumbent
Description

Acquired Gyroscope Therapeutics and its lead GT005 gene therapy program for geographic atrophy secondary to AMD. Comparable to Alkeus as a large-pharma participant in the GA competitive set and a potential strategic acquirer of late-stage ophthalmology biotechs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alkeus Pharmaceuticals

Ophthalmic Pharmaceuticalsalkeuspharma.com

Alkeus Pharmaceuticals is a private, clinical-stage biopharmaceutical company developing oral gildeuretinol acetate (ALK-001), an investigational therapy that reduces toxic vitamin A dimerization for Stargardt disease and geographic atrophy secondary to AMD. The Cambridge, Massachusetts company is conducting a pivotal global Phase 3 program.

What Alkeus Pharmaceuticals does

Alkeus Pharmaceuticals, Inc. is a privately-held, clinical-stage biopharmaceutical company headquartered at 44 Brattle Street, Cambridge, Massachusetts. Founded in 2010 by Dr. Ilyas Washington and Dr. Leonide Saad, the company is developing a single lead investigational therapy, oral gildeuretinol acetate (ALK-001), a new molecular entity designed to reduce the dimerization of vitamin A in the retina without modulating the visual cycle — a mechanism intended to prevent the accumulation of toxic vitamin A dimers that drive progression of Stargardt disease and geographic atrophy secondary to age-related macular degeneration. The company is pre-revenue and has no commercialized products.

The clinical pipeline is structured around three core programs. The pivotal global Phase 3 NORTHSTAR study is enrolling approximately 230 participants aged 8 to 45 with Stargardt disease across 55 sites in more than 11 countries, with primary endpoint of atrophic lesion growth rate. The TEASE program (four studies: TEASE-1 and TEASE-2 completed, TEASE-3 and TEASE-4 ongoing) covers Stargardt patients across advanced, moderate, and early-stage disease plus an open-label extension; TEASE-1 demonstrated a 21.6% reduction in atrophic lesion growth versus placebo (p<0.001). The SAGA study in 198 patients with geographic atrophy showed a 15.3% statistically significant reduction in GA lesion growth from 6 to 24 months (p=0.047) and preservation of 4.4 letters of low luminance visual acuity (p=0.031). Cumulative exposure exceeds 400 patients with a well-tolerated safety profile.

Alkeus's business model is a standard specialty pharmaceutical one-time license / prescription-revenue model contingent on FDA approval, with planned commercialization through traditional pharmaceutical distribution channels targeting retina specialists. The company is backed by institutional investors led by Bain Capital Life Sciences, which led a $150 million Series B financing in June 2023 alongside Sofinnova Investments, TCG Crossover, and Wellington Management. Gildeuretinol has received Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA, plus Orphan Medicinal Product designation from the EMA. Leadership was substantially rebuilt in 2024-2025 with the appointment of Michel Dahan (President and CEO, formerly COO of Akebia Therapeutics), David Arkowitz (CFO), Tamara Dillon (CHRO), Eric Trachtenberg (CLO), Srinivas Duggirala (SVP, Technical Operations), and Carlos Quezada-Ruiz (CMO, formerly SVP/Ophthalmology Therapeutic Area Head at 4D Molecular Therapeutics and senior leader at Genentech/Roche ophthalmology).

Alkeus Pharmaceuticals firmographics

Firmographics
Name
Alkeus Pharmaceuticals
Legal name
Alkeus Pharmaceuticals, Inc.
Website
https://alkeuspharma.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Alkeus Pharmaceuticals is a private, clinical-stage biopharmaceutical company developing oral gildeuretinol acetate (ALK-001), an investigational therapy that reduces toxic vitamin A dimerization for Stargardt disease and geographic atrophy secondary to AMD. The Cambridge, Massachusetts company is conducting a pivotal global Phase 3 program.
Ownership category
akta.pro rank

Alkeus Pharmaceuticals industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic pharmaceuticals
  • Retinal disease therapeutics
  • Stargardt disease treatment
  • Geographic atrophy therapy
  • Investigational drug development

Where Alkeus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alkeus Pharmaceuticals business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue biopharmaceutical company developing gildeuretinol (ALK-001) for Stargardt disease and geographic atrophy. The company plans to commercialize the therapy upon FDA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Alkeus Pharmaceuticals product offering

Product offering

Core offering

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company developing gildeuretinol acetate (ALK-001), an oral investigational therapy designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. The product is being advanced in clinical trials for Stargardt disease (TEASE program and pivotal Phase 3 NORTHSTAR study) and geographic atrophy secondary to age-related macular degeneration (SAGA study). The company is pre-revenue and intends to commercialize the therapy upon FDA approval, distributing it through traditional pharmaceutical channels prescribed by retina specialists.

Product overview

Alkeus Pharmaceuticals is a biopharmaceutical company developing a single lead candidate, gildeuretinol acetate (ALK-001), an oral new molecular entity designed to reduce toxic vitamin A dimerization without modulating the visual cycle. The product is being advanced through multiple clinical trial programs: the pivotal Phase 3 NORTHSTAR Study for Stargardt disease, the TEASE program (four studies spanning advanced, moderate, early-stage, and extension phases) for Stargardt disease, and the SAGA study for geographic atrophy secondary to AMD. The company has no commercialized products and all offerings are investigational therapies in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gildeuretinol Acetate (ALK-001) Oral investigational new molecular entity (capsule, once daily) designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. It is Alkeus's lead clinical candidate, in development for Stargardt disease and geographic atrophy secondary to age-related macular degeneration.
  • NORTHSTAR Phase 3 Study (Gildeuretinol) Pivotal clinical trial program evaluating oral gildeuretinol acetate in patients with Stargardt disease; designed to support regulatory approval.
  • TEASE Program (TEASE-1, TEASE-2, TEASE-3, TEASE-4) Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) program—four studies across advanced, moderate, early-stage, and extension phases evaluating oral gildeuretinol in Stargardt disease.
  • SAGA Study (Gildeuretinol in Geographic Atrophy) Clinical study evaluating oral gildeuretinol in 198 patients with geographic atrophy (GA) secondary to age-related macular degeneration, with the primary efficacy endpoint of GA lesion growth rate measured by Fundus Autofluorescence.

Quantifiable outcome

  • 21.6% reduction in atrophic retinal lesion growth vs placebo (p<0.001) in TEASE-1 study
  • +3 more outcomes

Companies that use Alkeus Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Alkeus Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Alkeus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Prevent BlindnesssupportingGTM or Marketing PartnerAlkeus serves as Silver Sponsor for Prevent Blindness's third annual Inherited Retinal Disease (IRD) and Genetic Testing Month initiative. The partnership supports education about Stargardt disease and genetic testing for early diagnosis and treatment planning.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Alkeus Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Apellis Pharmaceuticals: Commercial-stage biotech with Syfovre (pegcetacoplan) approved for geographic atrophy secondary to AMD. Directly comparable to Alkeus because both target the same large GA population with a retinal-disease focus, although Apellis uses a complement-inhibitor intravitreal approach versus gildeuretinol's oral vitamin A dimerization mechanism.
  • Astellas Pharma (Iveric Bio): Acquired Iveric Bio and now markets Izervay (avacincaptad pegol) for geographic atrophy secondary to AMD. A direct competitor in the GA market and a benchmark for late-stage ophthalmology biotech acquisition by big pharma — a relevant strategic exit template for Alkeus.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company targeting inherited retinal diseases including ABCA4-related conditions. Highly comparable to Alkeus because it operates in the same rare ophthalmology space with a focus on inherited retinal dystrophies, and its former SVP/Ophthalmology TA Head (Carlos Quezada-Ruiz) is now Alkeus's CMO.
  • Kodiak Sciences: Clinical-stage ophthalmology company developing therapeutics for retinal diseases including AMD. Comparable to Alkeus as a retinal-focused biotech pursuing novel mechanisms for high-prevalence retinal indications with a similar pre-commercial, late-stage clinical profile.
  • Adverum Biotechnologies: Gene therapy company focused on serious ocular diseases, with lead programs in wet AMD and diabetic macular edema. Comparable as a late-stage ophthalmology biotech targeting retinal vascular and degenerative indications with a similar clinical-stage, capital-intensive profile.
  • REGENXBIO: Clinical-stage gene therapy company with programs in retinal diseases (wet AMD, diabetic retinopathy) and rare ophthalmology. Comparable to Alkeus as a retinal-disease-focused biotech pursuing novel modality approaches for sight-threatening conditions.

Emerging players

  • Aldeyra Therapeutics: Clinical-stage biotech developing therapies for rare ocular and inflammatory diseases, including retinitis pigmentosa and other retinal conditions. Comparable to Alkeus as a small-cap, late-clinical-stage rare-ophthalmology biotech with similar regulatory pathway dynamics.
  • Annexon Biosciences: Clinical-stage biotech with a lead program (vonaprument) in geographic atrophy secondary to AMD. Comparable to Alkeus as a clinical-stage retina competitor in GA with similar pre-commercial profile and indication overlap.
  • Ocugen: Clinical-stage biotech with a pipeline including inherited retinal disease programs (e.g., Stargardt and other ABCA4-related dystrophies via OCU410ST). Direct competitor to Alkeus in Stargardt disease, pursuing a gene-therapy modifier approach rather than an oral small molecule.

Broad incumbents

  • Novartis (Gyroscope Therapeutics): Acquired Gyroscope Therapeutics and its lead GT005 gene therapy program for geographic atrophy secondary to AMD. Comparable to Alkeus as a large-pharma participant in the GA competitive set and a potential strategic acquirer of late-stage ophthalmology biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Alkeus Pharmaceuticals social profiles

Digital presence

Alkeus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alkeus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Alkeus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alkeus Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alkeus Pharmaceuticals

What does Alkeus Pharmaceuticals do?

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company developing gildeuretinol acetate (ALK-001), an oral investigational therapy designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. The product is being advanced in clinical trials for Stargardt disease (TEASE program and pivotal Phase 3 NORTHSTAR study) and geographic atrophy secondary to age-related macular degeneration (SAGA study). The company is pre-revenue and intends to commercialize the therapy upon FDA approval, distributing it through traditional pharmaceutical channels prescribed by retina specialists.

Is Alkeus Pharmaceuticals a public or private company?

Alkeus Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alkeus Pharmaceuticals founded?

Alkeus Pharmaceuticals was founded in 2010. It employs 51 to 100 people.

Where is Alkeus Pharmaceuticals based?

Alkeus Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

How does Alkeus Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Alkeus Pharmaceuticals's main competitors?

Direct peers on record are Apellis Pharmaceuticals, Astellas Pharma (Iveric Bio), 4D Molecular Therapeutics, Kodiak Sciences, Adverum Biotechnologies and REGENXBIO. Emerging players are Aldeyra Therapeutics, Annexon Biosciences and Ocugen. Novartis (Gyroscope Therapeutics) is listed as a broad incumbent.

Does Alkeus Pharmaceuticals have an API?

No public API is recorded for Alkeus Pharmaceuticals.

What industry is Alkeus Pharmaceuticals in?

Alkeus Pharmaceuticals's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyAlkeus trial shows oral pill slows vision loss in Stargardt diseaseAlkeus published TEASE-1 trial results showing oral Gildeuretinol reduced retinal atrophic lesion growth by 21.6% in Stargardt disease. The 50-patient trial also reported a 29.3% reduction in untransformed lesion area, with the drug well tolerated through 24 months. Alkeus is enrolling the global Phase 3 NORTHSTAR trial.AInvestTARS Just Printed a Fresh 52-Week High at $91.53 — $92 Decides Whether This Vertical Run Accelerates or Traps Late BuyersTarsus Pharmaceuticals hit a 52-week high of $91.53 after closing its $800M Alkeus acquisition, which includes gildeuretinol for Stargardt disease. The stock is up 40% monthly, with $92 as the key threshold for sustained momentum. A close above $91.53 could target $100, while falling below $80 risks a sharp correction.Quiver QuantitativeTarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline | TARS Stock NewsTarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol (ALK-001), an oral investigational treatment for Stargardt disease. The drug, which has received multiple FDA designations, is in Phase 3 NORTHSTAR trial with topline data expected in 2029.Stock TitanTarsus Closes Alkeus Acquisition, Adds Phase 3 ProgramTarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, adding worldwide rights to ALK-001, a Phase 3 oral investigational medicine for Stargardt disease. The drug has received multiple FDA designations and is in the global NORTHSTAR trial, with topline data anticipated in 2029.BioSpaceTarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareTarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, adding worldwide rights to ALK-001, an oral investigational medicine for Stargardt disease. The drug has received multiple FDA designations and is in the global NORTHSTAR Phase 3 trial, with topline data anticipated in 2029.AInvestTarsus: One Product, Five Factors, and the $450M QuestionTarsus Pharmaceuticals reported a record quarter with net product sales of $451.4 million, up 150% year over year, and raised its 2026 sales forecast. It agreed to acquire Alkeus Pharmaceuticals for $450 million, with Phase 3 data expected in 2029. The stock rose 21% over the past month to $74.FinancialContent Business PageAlkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt DiseaseAlkeus Pharmaceuticals announced that the Japan Ministry of Health, Labour and Welfare granted Orphan Drug Designation for its investigational drug gildeuretinol to treat Stargardt disease. This designation provides eligibility for development cost subsidies and potential market exclusivity, supporting the ongoing global Phase 3 NORTHSTAR clinical trial. The announcement comes as Alkeus is currently being acquired by Tarsus Pharmaceuticals.BioSpaceAlkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt DiseaseAlkeus Pharmaceuticals announced that Japan's MHLW granted orphan drug designation to gildeuretinol for Stargardt disease. The drug is in global Phase 3 NORTHSTAR study, with about 230 participants planned. Japan's designation offers subsidies and potential 10-year market exclusivity.Ophthalmology TimesBreakthrough Therapy Designation granted by FDA for Alkeus Pharmaceuticals’ ALK-001 Stargardt disease treatmentThe FDA has granted Breakthrough Therapy Designation to Alkeus Pharmaceuticals' ALK-001 for the treatment of Stargardt disease, following positive results from a Phase 2 clinical trial. This designation makes ALK-001 the only drug to receive this status for the condition and provides a strong basis for regulatory filing. Alkeus Pharmaceuticals plans to report data from ongoing trials for dry age-related macular degeneration later this year.Ophthalmology TimesAlkeus Pharmaceuticals announces results from the SAGA study of oral gildeuretinol in patients with GAAlkeus Pharmaceuticals announced that oral gildeuretinol achieved a clinically meaningful reduction in geographic atrophy lesion growth over 24 months in the SAGA study. The company confirmed these topline data were accepted as a late breaker for presentation at the upcoming American Academy of Ophthalmology annual meeting.